Triptolide ameliorates autoimmune diabetes and prolongs islet graft survival in nonobese diabetic mice
Shing-Hwa
Huang1,
Gu-Jiun
Lin2,
Chi-Hong
Chu1,
Jyh-Cherng
Yu1,
Teng-Wei
Chen1,
Yuan-Wu
Chen3, 4,
Ming-Wei
Chien5,
Chin-Chen
Chu6, 7 and
Huey-Kang
Sytwu5, 8*
-
1
Tri-Service General Hospital, Department of General Surgery, Taiwan
-
2
Department of Biology and Anatomy, National Defense Medical Center, Taiwan
-
3
National Defense Medical Center, School of Dentistry, Taiwan
-
4
Tri-Service General Hospital, Department of Oral and Maxillofacial Surgery, Taiwan
-
5
National Defense Medical Center, Graduate Institute of Life Sciences, Taiwan
-
6
Chi Mei Medical Center, Department of Anesthesiology, Taiwan
-
7
Chia Nan University of Pharmacy & Science, Department of Recreation and Health-Care Management, Taiwan
-
8
National Defense Medical Center, Department of Microbiology and Immunology, Taiwan
Triptolide (TPL) possesses profound immunosuppressive effects and has potential in allograft transplantation. We investigated whether TPL treatment prevents autoimmune diabetes in nonobese diabetic (NOD) mice and prolongs the survival of islet grafts against autoimmune attack or allograft rejection. In this study, diabetic incidence was monitored in TPL-treated NOD mice. NOD or BALB/c islets were transplanted into diabetic recipients treated with TPL. Different T cell subsets in grafts or spleen were analyzed. The proliferation, apoptosis, cytokines and activities of AKT, NF-κB, caspases 3, 8 and 9 of T cells were determined. Our results revealed that diabetic incidence was reduced and inflammatory cytokines were decreased in islets and spleen under TPL treatment. T cell proliferation was reduced and the survival of syngeneic or allogeneic grafts was significantly increased in TPL-treated mice. The populations of CD4, CD8, CD4CD69, CD8DC69 and IFN-r-producing T cells in islet grafts and spleen were reduced. TPL treatment increased the apoptosis of T cells in the spleen of recipients. Levels of p-AKT and p-IκB in splenocytes were reduced and caspase-3, -8 and -9 were increased in TPL-treated mice. In conclusion, TPL treatment not only reduced the diabetic incidence in NOD mice but also prolonged the survival of syngeneic or allogeneic grafts.
Keywords:
Triptolide,
type 1 diabetes,
Islet Transplantation,
NOD mice,
autoimmune recurrence,
allograft rejection
Conference:
15th International Congress of Immunology (ICI), Milan, Italy, 22 Aug - 27 Aug, 2013.
Presentation Type:
Abstract
Topic:
Translational immunology and immune intervention
Citation:
Huang
S,
Lin
G,
Chu
C,
Yu
J,
Chen
T,
Chen
Y,
Chien
M,
Chu
C and
Sytwu
H
(2013). Triptolide ameliorates autoimmune diabetes and prolongs islet graft survival in nonobese diabetic mice.
Front. Immunol.
Conference Abstract:
15th International Congress of Immunology (ICI).
doi: 10.3389/conf.fimmu.2013.02.00128
Copyright:
The abstracts in this collection have not been subject to any Frontiers peer review or checks, and are not endorsed by Frontiers.
They are made available through the Frontiers publishing platform as a service to conference organizers and presenters.
The copyright in the individual abstracts is owned by the author of each abstract or his/her employer unless otherwise stated.
Each abstract, as well as the collection of abstracts, are published under a Creative Commons CC-BY 4.0 (attribution) licence (https://creativecommons.org/licenses/by/4.0/) and may thus be reproduced, translated, adapted and be the subject of derivative works provided the authors and Frontiers are attributed.
For Frontiers’ terms and conditions please see https://www.frontiersin.org/legal/terms-and-conditions.
Received:
11 Mar 2013;
Published Online:
22 Aug 2013.
*
Correspondence:
Prof. Huey-Kang Sytwu, National Defense Medical Center, Graduate Institute of Life Sciences, Taipei, Taiwan, sytwn@ndmctsgh.edu.tw